Eisai will present five-year outcomes for lecanemab from the Clarity AD core and long-term extension phases at CTAD 2026, alongside the LEADER retrospective study of real-world use across diverse US clinical settings. The program includes data on ARIA rates across countries, subcutaneous versus intravenous administration, CSF proteomics, and biomarker durability after treatment discontinuation. Extended follow-up of an approved anti-amyloid therapy addresses the central unanswered question in this class: whether early intervention alters disease trajectory over years rather than months.
Key Points
- Five-year Clarity AD extension data among longest anti-amyloid follow-up reported
- LEADER study examines real-world lecanemab use three years post-approval
- Abstracts cover ARIA safety, subcutaneous dosing, biomarker durability after discontinuation
Longevity Analysis
Amyloid-targeting therapy tests a specific proposition — that removing an accumulated interference allows neural tissue to maintain function longer — and five-year data is the first meaningful opportunity to judge whether the effect compounds or plateaus. Biomarker durability after discontinuation matters most for practitioners, since it determines whether treatment is a finite intervention or an indefinite commitment, and the ARIA rates across varied clinical settings define the vascular risk that must be weighed against cognitive benefit. Real-world evidence from diverse populations also tests whether outcomes observed under trial conditions survive contact with ordinary practice, where monitoring intensity and patient selection differ substantially.
Original published by LT Wire.